Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past ...

In February 2025, Regeneron initiated a quarterly cash dividend program and declared a dividend of $0.88 per share. The board also authorized an additional $3.0 billion share repurchase program ...

Finally, Regeneron recently initiated a dividend in addition to its already attractive share-buyback program; the company clearly intends to reward its shareholders. That's another good reason to ...

Then I take a look at the company’s new dividend and buyback strategy, and how that gives me confidence in Regeneron’s long-term cash flow capabilities. In Q4 of 2024, Regeneron reported $1.5B ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% from ...

In a longer-term context, Regeneron's total shareholder return, including dividends, was a decline of 8.37% over the past five years. This performance trails the past year's market return of 8% and ...

The Company announced a 10-year agreement with FUJIFILM Diosynth Biotechnologies (Fujifilm) to manufacture and supply Regeneron's commercial bulk drug product at Fujifilm's North Carolina campus.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Company announced a 10-year agreement with FUJIFILM Diosynth Biotechnologies (Fujifilm) to manufacture and supply Regeneron's commercial bulk drug product at Fujifilm's North Carolina campus. The ...